As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Neogenomics, Inc. The largest reported stake is BlackRock, Inc.'s, at 15.6%. 15 filings are on record since July 17, 2025 (Schedule 13G/A, July 30, 2026).
Sell to companies like Neogenomics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: First Light Asset Management, LLC · Sole voting: 0 · Shared voting: 10,260,186 · Sole dispositive: 0 · Shared dispositive: 10,260,186 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: BlackRock, Inc. · Sole voting: 19,688,877 · Shared voting: 0 · Sole dispositive: 20,358,331 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-30
- · Reporting person: First Trust Portfolios L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-30
- · Reporting person: Greenhouse Funds LLLP · Sole voting: 0 · Shared voting: 8,318,358 · Sole dispositive: 0 · Shared dispositive: 9,215,903 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Millennium Management LLC · Percent: 1.7% · SCHEDULE 13G/A
Neogenomics, Inc. has 15 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| BlackRock, Inc. | 15.6% | 20,358,331 | SCHEDULE 13G/A, 2026-07-30 | 2026-06-30 |
| 8.37% | 10,759,586 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 | |
| First Trust Portfolios L.P. | 7.77% | 10,113,261 | SCHEDULE 13G, 2026-07-30 | 2026-06-30 |
| Greenhouse Funds LLLP | 7.1% | 9,215,903 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Vanguard Portfolio Management | 5.91% | 7,677,794 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Vanguard Capital Management | 5.09% | 6,610,272 | SCHEDULE 13G, 2026-04-30 | 2026-03-31 |
| Millennium Management LLC | 2.8% | 3,566,808 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Millennium Management LLC | 1.7% | 2,222,757 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Neogenomics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Neogenomics, Inc. and the records around it.
Neogenomics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Greenhouse Funds LLLP also filed stake reports on 5 other companies: NCR Voyix Corp (Sep 2026), Clarus Corporation (May 2026), PHREESIA, INC. (Feb 2026)
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026), Edesa Biotech, Inc. (Nov 2026)
Watch Neogenomics, Inc.
Get an email when Neogenomics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neogenomics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Neogenomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neogenomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 19,688,877 | 0 | 20,358,331 | 0 | SCHEDULE 13G/A, 2026-07-30 |
| First Light Asset Management, LLC | 0 | 10,260,186 | 0 | 10,260,186 | SCHEDULE 13G/A, 2026-08-14 |
| Mathew P. Arens | 235,000 | 10,524,586 | 235,000 | 10,524,586 | SCHEDULE 13G/A, 2026-08-14 |
| First Trust Portfolios L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2026-07-30 |
| First Trust Advisors L.P. | 0 | 10,113,261 | 0 | 10,113,261 | SCHEDULE 13G, 2026-07-30 |
| The Charger Corporation | 0 | 10,113,261 | 0 | 10,113,261 | SCHEDULE 13G, 2026-07-30 |
| Greenhouse Funds LLLP | 0 | 8,318,358 | 0 | 9,215,903 | SCHEDULE 13G/A, 2026-05-15 |
| Greenhouse GP LLC | 0 | 8,318,358 | 0 | 9,215,903 | SCHEDULE 13G/A, 2026-05-15 |
| Joseph Milano | 0 | 8,318,358 | 0 | 9,215,903 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Neogenomics, Inc. by CUSIP 64049M209 and gives its principal executive office as 9490 NeoGenomics Way, Fort Myers, FL 33912 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | Millennium Management LLC | 2.8% | SCHEDULE 13G/A |
| 2025-08-13 | Greenhouse Funds LLLP | 5.8% | SCHEDULE 13G |
| 2025-08-14 | Mathew P. Arens | 7.57% | SCHEDULE 13G |
| 2025-10-17 | BlackRock, Inc. | 14.6% | SCHEDULE 13G/A |
| 2025-12-02 | Millennium Management LLC | 4.97% | SCHEDULE 13G |
| 2025-12-09 | Millennium Management LLC | 5% | SCHEDULE 13G |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Portfolio Management | 5.91% | SCHEDULE 13G |
| 2026-04-30 | Vanguard Capital Management | 5.09% | SCHEDULE 13G |
| 2026-05-07 | Mathew P. Arens | 10.82% | SCHEDULE 13G/A |
| 2026-05-13 | Millennium Management LLC | 1.7% | SCHEDULE 13G/A |
| 2026-05-15 | Greenhouse Funds LLLP | 7.1% | SCHEDULE 13G/A |
| 2026-07-30 | First Trust Portfolios L.P. | 7.77% | SCHEDULE 13G |
| 2026-07-30 | BlackRock, Inc. | 15.6% | SCHEDULE 13G/A |
| 2026-08-14 | Mathew P. Arens | 8.37% | SCHEDULE 13G/A |
Questions about who owns Neogenomics, Inc.
Who owns Neogenomics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Neogenomics, Inc.: BlackRock, Inc. (15.6%, Schedule 13G/A, filed 2026-07-30), Mathew P. Arens (8.37%, Schedule 13G/A, filed 2026-08-14), First Trust Portfolios L.P. (7.77%, Schedule 13G, filed 2026-07-30), Greenhouse Funds LLLP (7.1%, Schedule 13G/A, filed 2026-05-15) and Vanguard Portfolio Management (5.91%, Schedule 13G, filed 2026-04-29); 1 more is listed above.
Who are the largest shareholders of Neogenomics, Inc.?
By the share each holder's latest filing reports, the largest holders of Neogenomics, Inc. on this page are BlackRock, Inc. (15.6%), Mathew P. Arens (8.37%) and First Trust Portfolios L.P. (7.77%).
When did BlackRock, Inc. buy into Neogenomics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from BlackRock, Inc. on this page is the Schedule 13G/A, filed 2025-10-17, reporting 14.6%; its latest, Schedule 13G/A filed 2026-07-30, reports 15.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Neogenomics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 5, 2026 | Leadership change: Lynn Tetrault departs, Chair of the Board | — | Leadership changes | Source |
| August 11, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| June 25, 2026 | Leadership change: Carolyn S. Starrett appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Neogenomics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.